BRPI1004899B8 - composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto - Google Patents

composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Info

Publication number
BRPI1004899B8
BRPI1004899B8 BRPI1004899A BRPI1004899A BRPI1004899B8 BR PI1004899 B8 BRPI1004899 B8 BR PI1004899B8 BR PI1004899 A BRPI1004899 A BR PI1004899A BR PI1004899 A BRPI1004899 A BR PI1004899A BR PI1004899 B8 BRPI1004899 B8 BR PI1004899B8
Authority
BR
Brazil
Prior art keywords
compound
phosphoinositide
pharmaceutical composition
kinase inhibitor
kinase
Prior art date
Application number
BRPI1004899A
Other languages
English (en)
Inventor
Qian Changgeng
- Jung Lai Cheng
Zhai Haixiao
Cai Xiong
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of BRPI1004899A2 publication Critical patent/BRPI1004899A2/pt
Publication of BRPI1004899B1 publication Critical patent/BRPI1004899B1/pt
Publication of BRPI1004899B8 publication Critical patent/BRPI1004899B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto, composição farmacêutica e uso de um composto o presente pedido se refere a deazapurinas, tienopirimidinas e furopirimidinas com derivados à base de metade de ligação a zinco e seu uso no tratamento de doenças e distúrbios relacionados a fosfoinositida 3-quinase, tal como câncer. o presente pedido ainda se refere ao tratamento de distúrbios e doenças relativos a histona deacetilase com respeito a ambos histona deacetilase e fosfoinositida 3-quinase.
BRPI1004899A 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto BRPI1004899B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14327109P 2009-01-08 2009-01-08
US61/143,271 2009-01-08
US17258009P 2009-04-24 2009-04-24
US61/172,580 2009-04-24
PCT/US2010/020495 WO2010080996A1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (3)

Publication Number Publication Date
BRPI1004899A2 BRPI1004899A2 (pt) 2016-04-05
BRPI1004899B1 BRPI1004899B1 (pt) 2020-08-18
BRPI1004899B8 true BRPI1004899B8 (pt) 2021-05-25

Family

ID=42316830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1004899A BRPI1004899B8 (pt) 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Country Status (25)

Country Link
US (11) US8367663B2 (pt)
EP (1) EP2385832B1 (pt)
JP (3) JP5452617B2 (pt)
KR (2) KR101430424B1 (pt)
CN (1) CN102341108B (pt)
AU (1) AU2010203512C1 (pt)
BR (1) BRPI1004899B8 (pt)
CA (1) CA2749228C (pt)
CY (1) CY1116797T1 (pt)
DK (1) DK2385832T3 (pt)
EA (1) EA024252B1 (pt)
ES (1) ES2550032T3 (pt)
HR (1) HRP20150947T1 (pt)
HU (1) HUE027615T2 (pt)
IL (2) IL213976A (pt)
ME (1) ME02230B (pt)
MX (1) MX2011007326A (pt)
PL (1) PL2385832T3 (pt)
PT (1) PT2385832E (pt)
RS (1) RS54230B1 (pt)
SG (2) SG196815A1 (pt)
SI (1) SI2385832T1 (pt)
SM (1) SMT201500226B (pt)
TW (1) TWI558710B (pt)
WO (1) WO2010080996A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385832B1 (en) 2009-01-08 2015-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
RU2595718C2 (ru) * 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
WO2012031563A1 (zh) * 2010-09-10 2012-03-15 杭州本生药业有限公司 杂环氨基小檗胺衍生物、其制备方法和应用
PL2640709T3 (pl) 2010-11-16 2016-10-31 Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania”
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
EA201300867A1 (ru) * 2011-01-27 2014-03-31 Дзе Трастиз Оф Принстон Юнивесити ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
CA2855446C (en) * 2011-11-23 2021-04-20 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
ES2806258T3 (es) 2013-12-03 2021-02-17 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
CR20170076A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CN104292242B (zh) * 2014-09-18 2017-05-17 广州必贝特医药技术有限公司 噻吩嘧啶类化合物和制剂及其制备方法和应用
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
BR112017005518B1 (pt) * 2014-12-11 2022-11-29 Natco Pharma Limited Derivados de 7-(morfolinil)-2-(n-piperazinil) metil-tieno [2, 3-c] piridina como drogas anticancerígenas
CA2983042C (en) * 2015-04-21 2020-01-07 Lijuan Chen Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
EP3380476B1 (en) * 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
SG11201901197PA (en) 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
CA3040727A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2021012639A (es) * 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
JP7467423B2 (ja) * 2018-09-11 2024-04-15 キュリス，インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
IL321451A (en) 2018-11-21 2025-08-01 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
IL285020B2 (en) * 2019-02-06 2025-11-01 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
UY38912A (es) 2019-10-09 2021-05-31 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
MX2022010258A (es) 2020-02-21 2023-01-24 Univ Case Western Reserve Composiciones y métodos para tratar la lesión renal.
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
CN115135659B (zh) * 2021-01-15 2024-03-12 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
JP7736782B2 (ja) * 2021-03-29 2025-09-09 株式会社カネカ （２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113754680B (zh) * 2021-09-28 2022-07-22 云白药征武科技(上海)有限公司 一种α氟代酰基哌嗪衍生物及其制备和应用
EP4410795A4 (en) * 2021-09-30 2025-10-01 Hanmi Pharmaceutical Co Ltd PIKFYVE KINASE INHIBITOR
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN117865979A (zh) * 2024-01-04 2024-04-12 广州必贝特医药股份有限公司 噻吩嘧啶类化合物的晶型及其制备方法
CN119161359B (zh) * 2024-09-18 2026-03-20 辽宁大学 一种新型含丙烯酰胺结构的4-吗啉基噻吩并[3,2-d]嘧啶类化合物及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AU6410699A (en) * 1998-10-13 2000-05-01 Chris Cheah Method and system for controlled distribution of information over a network
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
CA2476067C (en) 2002-03-13 2011-09-20 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
PT1591446E (pt) * 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7218492B2 (en) * 2004-09-17 2007-05-15 Electronic Polymers, Inc. Devices and systems for electrostatic discharge suppression
CA2583259C (en) 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7731753B2 (en) * 2005-09-01 2010-06-08 Spinal Kinetics, Inc. Prosthetic intervertebral discs
AU2006306462B2 (en) * 2005-10-24 2012-07-26 Biomet 3I, Llc Methods for manufacturing dental implant components
JP2007151829A (ja) * 2005-12-05 2007-06-21 Bridgestone Sports Co Ltd ゴルフクラブヘッド
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
DK1979328T3 (da) 2006-01-19 2013-03-25 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
JP5291616B2 (ja) * 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
CN101479274B (zh) * 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US8604044B2 (en) * 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
CA2662580C (en) * 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008033745A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
EP2061758A4 (en) * 2006-09-11 2011-11-30 Curis Inc A ZINC BINDING GROUP CONTAINING SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US20080234355A1 (en) * 2006-09-11 2008-09-25 Xiong Cai Dna methyl transferase inhibitors containing a zinc binding moiety
EP2049483A2 (en) 2006-10-28 2009-04-22 Methylgene, Inc. Inhibitors of histone deacetylase
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200922564A (en) * 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2702838A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
EP2214675B1 (en) * 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
EP2385832B1 (en) * 2009-01-08 2015-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CN102369011A (zh) * 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
NZ599939A (en) * 2009-10-12 2014-02-28 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
DK3111938T3 (da) * 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
KR101430424B1 (ko) 2014-08-14
SG196815A1 (en) 2014-02-13
CA2749228A1 (en) 2010-07-15
US10894795B2 (en) 2021-01-19
CN102341108A (zh) 2012-02-01
HUE027615T2 (en) 2016-10-28
AU2010203512C1 (en) 2013-10-17
IL237727A0 (en) 2015-05-31
US20250230169A1 (en) 2025-07-17
US20190352310A1 (en) 2019-11-21
SI2385832T1 (sl) 2015-10-30
AU2010203512A1 (en) 2011-08-11
DK2385832T3 (en) 2015-09-21
US20230227467A1 (en) 2023-07-20
EP2385832A1 (en) 2011-11-16
US9725461B2 (en) 2017-08-08
CA2749228C (en) 2016-05-17
AU2010203512B2 (en) 2013-03-14
PL2385832T3 (pl) 2016-01-29
ME02230B (me) 2016-02-20
US10676482B2 (en) 2020-06-09
JP5452617B2 (ja) 2014-03-26
US8367663B2 (en) 2013-02-05
TW201030009A (en) 2010-08-16
MX2011007326A (es) 2011-10-19
EP2385832A4 (en) 2012-07-25
US8906909B2 (en) 2014-12-09
US20120088764A1 (en) 2012-04-12
US20220402934A1 (en) 2022-12-22
IL213976A (en) 2015-03-31
US10336770B2 (en) 2019-07-02
US20140155595A1 (en) 2014-06-05
US20210214370A1 (en) 2021-07-15
US8461157B2 (en) 2013-06-11
BRPI1004899B1 (pt) 2020-08-18
CN102341108B (zh) 2015-05-27
US11597732B2 (en) 2023-03-07
US20150203509A1 (en) 2015-07-23
SG172908A1 (en) 2011-08-29
JP2015187145A (ja) 2015-10-29
SMT201500226B (it) 2015-10-30
US11261195B2 (en) 2022-03-01
CY1116797T1 (el) 2018-03-07
JP2014058571A (ja) 2014-04-03
WO2010080996A1 (en) 2010-07-15
EA201101053A1 (ru) 2012-02-28
TWI558710B (zh) 2016-11-21
HK1164113A1 (en) 2012-09-21
PT2385832E (pt) 2015-11-02
KR20110112404A (ko) 2011-10-12
US20170362251A1 (en) 2017-12-21
EA024252B1 (ru) 2016-08-31
JP2012514650A (ja) 2012-06-28
JP5762520B2 (ja) 2015-08-12
EP2385832B1 (en) 2015-07-15
KR20140094590A (ko) 2014-07-30
BRPI1004899A2 (pt) 2016-04-05
ES2550032T3 (es) 2015-11-04
HRP20150947T1 (hr) 2015-10-09
IL213976A0 (en) 2011-08-31
US20100222343A1 (en) 2010-09-02
RS54230B1 (sr) 2015-12-31
US20200339593A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
ECSP11010760A (es) Derivados de quinoxalindiona
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
MX2011013306A (es) Compuestos tetraciclicos.
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY32605A (es) Agentes antiinflamatorios como compuestos virostáticos
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
BR112012011328A2 (pt) inibidores de akt
SG196815A1 (en) Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: CURIS, INC. (US)